

Adela Prchlikova, Lucie Ehrlichova, Tomas Arpas, Martina Filipova, Zuzana Mrkvova, Stepan Tucek, Samuel Hricko, Dominik Fric, Stepan Hrabovsky.

Background


- Peripherally inserted central catheter (PICC) frequently serves as the device of first choice for the administration of oncological treatment.
- From January 2015 to November 2023 we implanted 2106 PICCs for total permanence of 273,022 catheter-days, mostly for immunochemotherapy administration (85%).

Objectives and methods

- We present a retrospective analysis evaluating development in insertion process and aftercare of PICCs during 9-year period at one of the largest hematological/oncological centers in Czechia.


Results

Diagnoses




Results


Overall development




Complications per 1000 catheter-days




Indications



Decrease in periprocedural complications with more PICCs implanted per person



Infection incidence per 1000 catheter-days



Conclusions

- PICC represents a **safe vascular access option** for patients undergoing immunochemotherapy.
- We can appreciate the **contribution of newly introduced methods** (iEKG, tunneling, securing with subcutaneously anchored device) in insertion process and aftercare of this vascular access.
- We detected **low incidence** of catheter related **infections** during the whole observed period.
- Furthermore, we emphasize the **importance** of the center's and also each individual's **experience** with this type of catheter, the **necessity of** continuous **education** of medical and non-medical personnel in the topic of vascular access.

References

- Mielke D, et al. Support Care Cancer. 2020 Oct;28(10):4753-4760
- Lacostena-Pérez ME, et al. Enferm Intensiva (Engl Ed). 2019 Jul-Sep;30(3):116-126

Acknowledgements

We thank all our patients, colleagues and medical personnel for participating in the treatment and this research.

Contact

Adela Prchlikova, prchlikova.adela@fnbrno.cz



Department of Internal Medicine,
Hematology and Oncology,
University Hospital Brno
and Masaryk University, School of Medicine

